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Abstract
Neonatal lupus erythematosus is a rare disorder caused by the
transplacental passage of maternal autoantibodies. The 52-kDa
Ro/SSA antigen (Ro52) ribonucleoprotein represents an
antigenic target strongly associated with the autoimmune
response in mothers whose children have neonatal lupus and
cardiac conduction disturbances, mainly congenital heart block.
The objective of this study was to identify putative Ro52/60-kDa
Ro/SSA antigen (Ro60) epitopes associated with neonatal
lupus and congenital heart block. The reactivity of IgG
antibodies present in the sera from mothers with systemic lupus
erythematosus and Sjögren's syndrome and in the sera from
asymptomatic mothers (a longitudinal study of 192 samples
from 66 subjects) was investigated by ELISA using Ro52, Ro60
and 48-kDa La/SSB antigen proteins, as well as 45 synthetic
peptides, 13–24 residues long, of Ro52/Ro60 proteins. One to
19 samples collected before, during and after pregnancy were
available for each mother. Forty-three disease controls selected
randomly and normal sera were tested in parallel. Although no
differences were found between Sjögren's syndrome and
asymptomatic mothers of group I, who had at least one infant
with neonatal lupus, and of group II, who had healthy babies
only, significant differences were observed between lupus
mothers from both groups. In the former group of lupus mothers,
a significantly higher frequency of antibodies to Ro52 peptides
107–122 and 277–292 was observed. Between 18 and 30
weeks of gestation, the period of risk, there was clearly an
elevated level of antibodies reacting with Ro52 peptides 1–13,
277–292 and 365–382. Antibodies to Ro52 peptide 365–382
have been shown previously to cross-react with residues 165–
185 of the heart 5-HT4 serotoninergic receptor, and might be
pathologically important. The level of these Ro52 antibody
subsets decreased at the end of pregnancy and after delivery.
IgG antibodies to Ro52 peptides 1–13, 107–122, 277–292
and 365–382 may therefore represent important biomarkers to
predict a complication in pregnant lupus women with Ro52
antibodies.
Introduction
Neonatal lupus erythematosus (NLE) is a rare, but severe, pas-
sively acquired autoimmune syndrome of neonates character-
ized by cardiac, dermatological, hepatic and hematological
manifestations. Autoimmune-associated congenital heart
block (CHB) is often detected between 18 and 24 weeks of
gestation and, to date, in its complete form, remains irreversi-
ble. In contrast, noncardiac manifestations are transient,
resolving by 1 year of age without specific treatment [1]. The
mothers of these children often have an autoimmune disorder
(i.e. systemic lupus erythematosus [SLE] and/or Sjögren's
syndrome [SS]), with antibodies against SSA/Ro and/or SSB/
La antigens. However, entirely asymptomatic mothers with
these antibodies (generally diagnosed after delivery) can also
CHB = congenital heart block; ELISA = enzyme-linked immunosorbent assay; 5-HT4-R, 5-HT4 receptor; La, 48-kDa La/SSB antigen; NLE, neonatal 
lupus erythematosus; OD, optical density; Ro52, 52-kDa Ro/SSA antigen; Ro60, 60-kDa Ro/SSA antigen; SLE, systemic lupus erythematosus; SS, 
Sjögren's syndrome.Arthritis Research & Therapy    Vol 8 No 1    Fritsch et al.
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give birth to infants with CHB. Maternal antibodies to the 52-
kDa Ro/SSA (Ro52) and 48-kDa La/SSB (La) antigens have
been reported to be more strongly associated with CHB than
antibodies to the 60-kDa (Ro60) alone [2,3]. The prevalence
of CHB in newborns of prospectively followed women with
anti-SSA antibodies and known autoimmune rheumatic dis-
ease is 2% [4].
Several lines of evidence support the pathogenic role of Ro
and La antibodies, which presumably cross the placenta and
damage the conduction system of the developing fetus. It is
notable, however, that abnormalities are not detectable in
maternal cardiac functions despite exposure to the identical
antibodies. The pathogenic role of maternal antibodies is
poorly understood. Direct implication of Ro/La antibodies has
been described in two studies of fatal CHB. Maternal IgG
bearing anti-La idiotypes were identified on the surface of fetal
cardiac myocytes [5] and Ro antibodies were found in an
affected fetal heart [6]. In addition, complete atrioventricular
block could be induced in the rabbit and human fetal heart
after perfusion of the aorta with anti-Ro52 antibodies [7,8].
These same antibodies inhibited the whole-cell and single-
channel L-type Ca2+ channels. The pathogenic role of Ro52
antibodies in the development of CHB was also supported by
an experiment using BALB/c mice as a murine model [9].
The association of CHB with maternal autoantibodies to Ro
and La antigens might be due to cross-reactions between
maternal anti-Ro/La antibodies and fetal cardiac-specific anti-
gens. A possible antigen targeted by La antibodies might be
laminin, a major component of the sarcolemmal membrane of
cardiomyocytes, which undergoes conformational changes
during development (residues EAKLRA are common to La and
B1 laminin) [10,11]. Molecular mimicry between these two
self-antigens could thus contribute to the pathogenesis of
CHB at an early stage during fetal cardiac development. We
have more recently identified a cross-reactive B-cell epitope
between the Ro52 protein (in residues 365–382) and the
heart 5-HT4 serotoninergic receptor (residues 165–185), and
have demonstrated that these cross-reactive antibodies
antagonized the serotonin-induced L-type Ca2+ channel acti-
vation on human atrial cells [12]. Further studies showed that
antibodies against the human 5-HT4 receptor (5-HT4-R) have
no intrinsic activity on the receptor itself but block receptor
activation on human atrial cells by the cognate hormone sero-
tonin [13]. Most importantly, it was also demonstrated that
pups from normal female mice immunized with the 5-HT4-R
peptide 165–185 showed bradycardia, atrioventricular blocks
of type I and type II, longer QT intervals, skin rash and neuro-
motoric problems [14]. We have thus clearly demonstrated
that anti-5-HT4-R antibodies are associated with neonatal
lupus, that they are pathogenic and that they cross-react with
the Ro52 antigen [12-14]. It is notable that while the 5-HT4-R
is not functional in adult rodents, it is expressed in mouse fetal
heart [14]. The expression of 5-HT4-R in the human fetal heart
has also been confirmed [15].
Although many questions remain to be solved to understand
the involvement of 5-HT4-R in the pathogenicity of CHB, the
quest for biomarkers that predict mothers at risk remains an
important challenge. In this study, we have tested the sera
from 66 mothers (a longitudinal study of 192 samples) in dif-
ferent clinical subgroups for the presence in their serum of IgG
antibodies reacting with Ro52, Ro60 and La proteins, as well
as with 39 synthetic peptides covering the whole sequence of
the Ro52 protein and with six peptides of the Ro60 protein.
The appearance of protein and peptide-reactive antibodies
was examined regularly in mothers before, during and after
delivery. The aim of this study was twofold; first, to determine
whether antibodies to the Ro52 peptide 365–382 are impor-
tant in predicting a complication in pregnant women with Ro
antibodies; and, second, to identify other putative Ro52
epitopes associated with neonatal lupus and CHB.
Patients and methods
Patients
Two groups of mothers were defined in this study (Table 1).
Group I was composed of 41 consecutive mothers who gave
birth to 58 children, of whom at least one infant per mother
was affected with NLE. In this group, 10 mothers had a lupus,
15 mothers had SS and 16 mothers were asymptomatic.
Among the 58 children of these 41 mothers, 45 children had
a CHB (14 males, 18 females, 13 unknowns), five children had
a cutaneous NLE (one male, four females), and eight children
were healthy (three males, four females, one unknown). The
diagnosis of complete CHB was based on fetal echocardiog-
raphy when the diagnosis of CHB was obtained during fetal
life, and was based on postnatal electrocardiogram when
bradycardia was detected. Among the 41 mothers who gave
birth to a child with NLE, four had a pregnancy that resulted in
at least one abortion after an in utero fetal demise or early
death of a baby younger than 6 months. These 41 mothers
were aged 19–56 years (average 32.9 years) when their blood
was collected, for some of them a long period of time after
pregnancy (maximum 12 years). Group II corresponded to 25
mothers with 30 healthy children. In this group, 18 mothers
had a lupus and seven mothers had an SS, the mothers were
aged 23–42 years (average 33.6 years) and three abortions
occurred. Patients selected in our study mainly presented
rheumatological and dermatological manifestations.
For patients with SLE, the symptoms were usually mild to mod-
erately severe, and generally no treatment was necessary by
the time surrounding pregnancy. Those who needed to be
treated were well controlled by either corticosteroids (about
5–20 mg/day Cortancyl®) or hydroxychloroquine (Plaquenil®).
The latter was in most cases interrupted during pregnancy.
Only a few mothers (3/22 documented lupus mothers)
required a more aggressive treatment such asAvailable online http://arthritis-research.com/content/8/1/R4
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cyclophosphamide (Endoxan®), which was replaced by corti-
costeroids during pregnancy. Plasmapheresis was realized to
prevent CHB when the risk was high. Aspirin was introduced
during pregnancy to prevent the risk of thrombosis.
From each mother of groups I and II, 1–19 serum samples
were available to study. A total of 192 sera from mothers were
tested all together. All of the women gave informed consent to
participate, and the study was approved by the Ethics Com-
mittee at the Paris Bichat-Claude Bernard Hospital. Disease
controls were studied in addition, including the serum from
patients with SLE (n = 14), with SS (n = 15) and with rheuma-
toid arthritis (RA; n = 14) selected randomly (women without
indication of pregnancy), and the sera from 24 healthy blood
donors were also tested. Lupus patients' sera were randomly
taken from the serum collection from one of the authors (DAI)
and no pre-selection according to disease manifestation or
severity was made. The global score (British Isles Lupus
Assessment Group system) used to measure the lupus dis-
ease severity of 14 female patients (aged 17–58 years; aver-
age 28.4 years) was between 1 and 22 (inactive/mildly active
disease, score 1–5, n = 6; moderately to severely active dis-
ease, score 6 or greater, n = 8). Eight of these patients were
Caucasian, four patients were Afro-Caucasian and two
patients were Chinese. Informed consent was obtained from
all participants in accordance with the medical ethical regula-
tions of the local committee. Sera were stored at -70°C until
use.
Ro proteins and Ro synthetic peptides
Affinity-purified Ro60 and La proteins were obtained from
Immunovision (ref. SSA-300; Springdale, AR, USA). The pro-
duction and purification of human recombinant Ro52 (rRo52),
a kind gift from G Pruijn and W van Venrooij (Nijmegen, The
Netherlands), has been described previously [16]. Synthesis
and purification of 39 overlapping peptides of Ro52 and of six
peptides of Ro60 have been described previously [16,17].
Ro52 peptides encompassed 13–24 amino acid residues
and, in general, overlapped each other by 1–10 residues.
Selection of peptides that have been synthesized have also
been made according to difficulties of synthesis and/or solu-
bility in aqueous solvents. The Ro60 peptide 21–41 was con-
jugated to ovalbumin through the -SH group of cysteine 38
using m-maleimido benzoyl-N-hydroxy succinimide ester as a
coupling agent [17].
ELISA, immunodiffusion and Western blotting
The methods used for testing antibodies reacting with rRo52,
Ro60 and La proteins in the three types of assay and Ro52/
Ro60 peptides in ELISA have been previously described
[16,17]. Only the IgG response was tested in the ELISA and
Western blotting assay. Peptides were found to be satisfacto-
rily attached to the plastic surface of ELISA plates using anti-
bodies induced in rabbits against these peptides [18]. For
calculations, all optical density (OD) values >3 measured in
the ELISA were considered as 3.0. The cutoff points of each
assay were determined from a series of sera collected from 24
normal donors using the mean OD values of these normal sera
tested in parallel + 2 standard deviations. For convenience,
the 192 sera screened with the 48 antigens (proteins and
peptides) were considered positive when OD ≥0.3. When this
threshold value was used, none of the normal sera was found
positive. Mean OD values correspond to the arithmetic mean
of all OD values, including values under the cutoff line for pos-
itivity. Statistically significant frequency differences between
groups were determined by Student's t test. Mean OD values
differences between groups were analyzed using the Mann-
Whitney U test. P < 0.05 was considered significant.
Results
Reactivity of mothers' sera with Ro52/Ro60 proteins and 
peptides
The sera from mothers with SLE and SS as well as sera from
asymptomatic mothers were tested with Ro proteins by immu-
nodiffusion, Western blotting and ELISA. Previous studies
have shown that distinct antibody subsets are identified using
these different immunoassays [16]. This observation was con-
firmed in the present study (Table 2). In general, the ELISA
detected Ro52 and Ro60 antibodies in a higher number of
sera than Western blotting. A number of sera were positive in
immunodiffusion tests but negative in ELISA and/or Western
blotting tests. Conversely, some immunodiffusion-negative
sera were positive in the ELISA and/or Western blotting tests.
It is noticeable, however, that Ro antibodies were more fre-
Table 1
Description of the study groups
Symptom Group I Group II Total
Mothers Children Mothers Children Mothers Children
Systemic lupus erythematosus 10 (24) 13 18 (91) 21 28 (115) 34
Sjögren's syndrome 15 (17) 26 7 (40) 9 22 (57) 35
Asymptomatic 16 (20) 19 0 0 16 (20) 19
Total 41 (61) 58 25 (131) 30 66 (192) 88
Numbers in parentheses indicate the number of serum samples tested in each group.Arthritis Research & Therapy    Vol 8 No 1    Fritsch et al.
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quently detected in the serum from patients with SLE and SS
than in the serum from asymptomatic mothers (Table 2). Inter-
estingly most of the sera from SLE, SS and asymptomatic
mothers contained antibodies reacting with both Ro52 and
Ro60. Very few sera contained antibodies reacting with only
one Ro protein (or with La only; data not shown), and this reac-
tivity profile was consistently observed in mothers of both
groups I and II. No statistically significant difference was
observed between the sera of groups I and II when the reac-
tivity of sera with the Ro52 and Ro60 proteins was examined.
The 192 sera from 41 mothers of group I and from 25 mothers
of group II were then tested for their ability to react in the
ELISA with 39 overlapping peptides covering the whole Ro52
sequence and with six Ro60 peptides. The reactivity of autoim-
mune sera with these 45 peptides has been described previ-
ously [16,17,19]. The data (frequency and P  values)
presented in Table 3 take into account the number of samples
collected from each mother that differs from 1 to 19. The anal-
ysis of data showed that, among the 45 peptides tested in
ELISA, only three (sequences 191–208, 262–279 and 326–
340 of Ro52) were never recognized by IgG antibodies con-
tained in the sera of groups I and II. Thirty-one other peptides
were recognized by less than 25% of sera, and 11 peptides
were recognized by at least 25% of sera (Table 3).
When the reactivity of SLE sera was analyzed and compared
in both groups I and II, we observed first that the spectrum of
reactivity of antibodies from mothers of group I was larger (11
peptides versus 5 peptides recognized by at least 25% of
sera). Second, we found that the level of IgG antibodies to
Ro52 peptide 107–122 (69% versus 28%; P = 0.023) and
peptide 277–292 (83% versus 49%; P = 0.049) and to Ro60
peptide 21–41 (64% versus 27%, P = 0.044) was more fre-
quently elevated in the serum from mothers of group I. These
differences were statistically significant with P ≤ 0.050. Some
peptides were recognized much more frequently by the anti-
bodies from mothers of group I, although in a non-statistically
significant manner; for example, with the Ro52 peptide 107–
126 (37% versus 7%; P = 0.062) and the Ro52 peptide 365–
382 (77% versus 47%; P = 0.054).
It is noticeable that in contrast to what was observed with the
sera from lupus mothers, the sera from mothers with SS
reacted with fewer Ro peptides; namely, four Ro52 peptides
(sequences 1–13, 107–122, 277–292 and 365–382) and
two Ro60 peptides (sequences 21–41 and 304–324), which
were recognized by at least 25% of sera. The percentage of
sera positive with these peptides in groups I and II was not sta-
tistically significantly different (Table 3).
The sera from asymptomatic mothers with affected children
collected 3 months-10 years after delivery (mean 4.8 years)
reacted weakly and infrequently with Ro52 and Ro60 peptides
(Table 3). The reactivity of sera with La protein follows the
same pattern of reactivity; namely, a highly significant elevation
of positive sera from lupus mothers of group I as compared
with lupus mothers of group II, positivity of sera from mothers
with SS that was not statistically different in groups I and II,
and a low frequency of positive sera in the group of asympto-
matic mothers of group I (Table 3).
If we considered a mother positive when at least one of sam-
ples was positive with a given peptide, instead of taking into
Table 2
Reactivity in different tests of sera from mothers of groups I and II
Mothers Immunodiffusion Western blotting ELISA
Ro (%) Ro52 (%) Ro60 (%) Ro52 (%) Ro60 (%)
Systemic lupus erythematosus
Group I (n = 9 mothers; 12 samples) 25 67 25 92 67
Group II (n = 14 mothers; 26 samples) 69 12 23 62 69
Total (n = 23 mothers; 38 samples) 47 39 24 77 68
Sjögren's syndrome
Group I (n = 14 mothers; 14 samples) 71 57 29 64 64
Group II (n = 6 mothers; 12 samples) 100 50 25 100 100
Total (n = 20 mothers; 26 samples) 86 54 27 82 82
Asymptomatic
Group I (n = 13 mothers; 13 samples) 38 23 8 31 38
The results are shown for mothers, the serum of whom has been systematically tested in the three assays. Only the IgG antibody response was 
tested in Western blotting and ELISA. The first figure in parentheses represents the number of mothers and the second represents the total 
number of samples tested. The data take into account the number of samples collected from each mother, which differs from 1 to 5. Thus, for each 
mother, the frequency of positivity (%) to each peptide was determined as the number of positive sera reported to the total number of samples.Available online http://arthritis-research.com/content/8/1/R4
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Table 3
Reactivity in ELISA of sera from mothers of groups I and II
Antigen Systemic lupus erythematosus Sjögren's syndrome Asymptomatic
Group I (%) Group II (%) P Group I (%) Group II (%) P Group I (%)
Recombinant Ro52 protein 97 66 0.009* 67 98 0.027* 31
1–13 MASAARLTMMWEE 77 46 0.084 47 58 31
10–25 MWEEVTPICLDPFVE 0 14 0 0 0
12–35 EEVTCPICLDPFVEPVSIECGHSF 10 16 20 8 13
25–40 EPVSIECGHSFCQECI 0 13 10 0 6
34–56 SFCQECISQVGKGGGSVCAVCRQ 0 1 7 0 13
38–53 ECISQVGKGGGSVCAV 3 4 7 0 0
50–64 VCAVCRQRFLLKNLR 25 3 13 5 6
63–79 LRPNRQLANMVNNLKEI 0 6 0 3 0
77–94 KEISQEAREGTQGERCAV 18 1 3 0 0
93–116 AVHGERLHLFCEKDGKALCWVCAQ 40 12 10 9 0
94–109 VHGERLHLFCEKDGKA 3 13 0 0 0
107–122 GKALCWVCAQSRKHRD 69 28 0.023* 47 33 13
107–126 GKALCWVCAQSRKHRDHAMV 37 7 0.062 13 8 13
121–137 RDHAMVPLEEAAQEYQE 0 4 0 0 0
135–151 YQEKLQVALGELRRKQE 3 14 0 0 0
149–166 KQELAEKLEVEIAIKRAD 0 12 0 1 0
164–180 RADWKKTVETQKSRIHA 0 9 0 0 6
178–193 IHAEFVQQKNFLVEEE 3 14 0 0 0
191–208 EEEQRQLQELEKDEREQL 0 0 0 0 0
206–224 EQLRILGEKEAKLAQQSQA 0 1 7 0 9
222–235 SQALQELISELDRRCHS 17 3 23 1 6
236–250 CHSSALELLQEVIIV 27 6 10 7 0
249–264 IVLERSESWNLKDLDI 0 5 7 0 0
262–279 LDITSPELRSVCHVPGLK 0 0 0 0 0
277–292 GLKKMLRTCAVHITLD 83 49 0.049* 40 24 6
290–304 TLDPDTANPWLILSE 0 7 7 0 0
302–317 LSEDRRQVRLGDTQQS 10 2 7 0 0
314–328 TQQSIPGNEERFDSY 0 9 0 9 0
326–340 DSYPMVLGAQHFHSG 0 0 0 0 0
337–352 FHSGKHYWEVDVTGKE 23 11 3 12 6
350–367 GKEAWDLGVCRDSVRRKG 0 1 0 0 9
365–382 RKGHFLLSSKSGFWTIWL 77 47 0.054 50 33 25
380–396 IWLWNKQKYEAGTYPQT 0 5 0 2 0
394–412 PQTPLHLQVPPCQVGIFLD 18 1 3 10 0
411–423 LDYEAGMVSFYNI 0 2 0 0 0
422–438 NITDHGSLIYSFSECAF 16 2 0 0 0Arthritis Research & Therapy    Vol 8 No 1    Fritsch et al.
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account the number of serum samples available for each
mother, very similar results were obtained. Between group I (n
= 10) and group II (n = 18) of mothers with lupus, statistically
different reactivities were found with Ro52 peptide 107–122
(88% versus 33%, P = 0.011), peptide 277–292 (100% ver-
sus 44%, P = 0.007) and peptide 365–382 (100% versus
61%, P = 0.039), and with Ro60 peptide 21–41 (75% versus
33%, P = 0.049) and peptide 304–324 (75% versus 33%, P
= 0.049). Reactivities with recombinant Ro52 protein (100%
versus 78%), Ro52 peptide 1–13 (88% versus 56%) and La
protein (100% versus 50%) were no longer statistically differ-
ent between groups I and II of lupus patients. No difference
was observed between groups I and II of mothers with SS.
In summary, the most significant differences observed
between mothers of groups I and II were in lupus mothers of
group I, who possessed a significantly higher frequency of IgG
antibodies to Ro52 peptides 107–122 and 277–292 and to
Ro60 peptide 21–41. In a series of disease control sera col-
lected from randomly selected patients with SLE, SS and RA,
the data showed that, in good agreement with our previous
results, the two Ro52 peptides were not recognized or were
recognized infrequently [16,19] by the sera from these
patients.
Longitudinal study of sera from lupus mothers of groups 
I and II
The data already described indicate that certain antibody sub-
types occur more frequently in the serum of lupus mothers of
children with NLE than in the samples from lupus mothers with
healthy children. The appearance of IgG antibodies to Ro
antigens (Ro52, Ro60, La proteins and the 45 peptides of
Ro52 and Ro60) was then examined in serial samples from
lupus mothers of groups I and II in order to establish, in a more
individual manner, whether correlations exist between the
presence of these antibody subsets and different parameters
related to the disease, the treatment and the course of preg-
nancy. Figure 1 shows longitudinal testing of sera from four
representative mothers. The cumulative data are reported in
Figure 2, in which we have subdivided the analysis into three
periods: before pregnancy (in a range of 18 months with a
mean at 11 weeks for group I, and in a range of 21 months with
a mean at 48 weeks for group II; Figure 2a,d), during preg-
nancy (Figure 2b,e) and after pregnancy (in a range of 26
months with a mean at 21 weeks for the group I, and in a range
of 12 months with a mean at 17 weeks for the group II; Figure
2c,f). In a general manner, whichever period is examined and
for most of the antibody specificities, the level of IgG antibod-
ies (expressed as mean OD values) and their frequency (%)
were clearly higher in the mothers of group I as compared with
mothers of group II. This observation is true for antibodies
reacting with several Ro peptides and for the antibodies to
whole Ro proteins (most particularly for La and Ro52 antibod-
ies). Before pregnancy, the levels of antibodies to Ro52 pep-
tides 277–292 and 365–382 (in terms of mean OD values) as
well as Ro52 peptides 1–13, 107–122 and 107–126 (in
terms of frequency) were particularly elevated in group I. Dur-
ing pregnancy the same antibodies except the antibodies to
Ro52 peptide 107–126 were also elevated, and after preg-
nancy antibodies to Ro52 peptides 277–292 and 365–382
were elevated.
436–451 CAFTGPLRPFFSPGFN 13 7 13 10 0
447–463 SPGFNDGGKNTAPLTLC 8 9 0 6 0
463–475 CPLNIGSQGSTDY 0 7 7 1 0
R o 6 0  P R O T E I N 8 06 7 6 79 9 0 . 0 2 2 * 3 1
1–23 MEESVNQMQPLNEKQIANSQDGY 15 6 17 1 6
18–38 NSQDGYVWQVTDMNRLHRFLC 32 11 20 1 0.097 0
21–41 DGYVWQVTDMNRLHRFLCFGS 64 27 0.044* 23 38 0
304–324 VCEKLCNEKLLKKARIHPFHI 50 18 27 4 13
495–518 KLIVCGMTSNGFTIADPDDRGMLD 10 24 0.058 7 11 0.079 13
524–538 TGALDVIRNFTLDMI 10 17 3 9 0
La PROTEIN 93 30 <0.00
01*
40 68 13
The 192 samples described in Table 1 were systematically tested in at least two independent tests. Only the IgG response was tested. Patients' 
sera were diluted 1:1,000. To be tested in the ELISA, peptide 21–41 of Ro60 protein was conjugated to ovalbumin. The sera were considered 
positive when optical density ≥0.3. Statistically significant differences between groups were determined by Student's t test. *P < 0.05 considered 
significant.
Table 3 (Continued)
Reactivity in ELISA of sera from mothers of groups I and IIAvailable online http://arthritis-research.com/content/8/1/R4
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In Figure 3, the analysis was further focused on the pregnancy
period and the data were examined by defining four testing
periods: weeks 1–8, weeks 16–20, weeks 26–30 and weeks
31–35 of pregnancy. Seven samples from five mothers and 24
samples from 17 mothers were examined for group I and
group II, respectively. The major features of this study were
that the overall level of antibodies was higher in the mothers of
group I as compared with group II, and that between 16 and
30 weeks of gestation, the period of risk, there was clearly an
elevated level of antibodies reacting with Ro52 peptides 1–
13, 277–292 and 365–382.
One of our patients with high levels of IgG antibodies reacting
with Ro60, rRo52, Ro52 peptides 1–13, 107–122, 277–292
and 365–382, and Ro60 peptide 21–41 was treated by plas-
mapheresis. This lupus mother had a first baby with CHB.
Plasmapheresis was used for her second pregnancy as a
method of treatment aimed at removing antibodies from her
plasma to decrease potential autoimmune activity after placen-
tal passage. IgG antibodies were efficiently removed from the
bloodstream as measured in serum samples collected
sequentially during her pregnancy. The mother gave birth to a
healthy child.
Discussion
The antigenic structure of Ro52, Ro60 and La has been exten-
sively studied by several independent groups, and a number of
dominant epitopes have been identified in these proteins [20-
22]. However, probably because the number of available sera
is relatively low, there are very few systematic mapping studies
aimed at the characterization of particular regions of Ro and La
antigens recognized by CHB-associated antibodies from
mothers of affected infants or, in this context, from children suf-
fering from NLE [11,23]. Studies with Ro antigens reported
the reactivity of selected sera with recombinant fragments
tested by ELISA and Western blotting assay, and it was found
that anti-Ro reactivity in mothers of infants with CHB reacted
mainly against the Ro52 sequence 200–239, whereas the
predominant activity in control mothers was against the
sequence 176–196 [23]. This result was confirmed with syn-
thetic peptides, and the most recent study demonstrated that
pups born from rats immunized with the Ro52 peptide 200–
239 developed atrioventricular block [24]. In the present
Figure 1
Longitudinal study of sera from lupus mothers of groups I and II with Ro antigens Longitudinal study of sera from lupus mothers of groups I and II with Ro antigens. The sera from lupus mothers of (a) group I and (b)–(d) group II 
were tested by ELISA before (b), during (g, for gestation) and after (p, for post) pregnancy. The number of weeks is indicated. Mother D had two 
consecutive pregnancies (D1 and D2). The rectangles represent the period known to be at risk (approximately weeks 16–26 of gestation), knowing 
that autoimmune-associated congenital heart block most often occurs between 18 and 24 weeks of gestation. Sera were tested at a 1:1,000 dilu-
tion. Only the IgG response was evaluated. All samples were systematically tested in at least two independent tests – the results shown in the figure 
correspond to one complete representative experiment. The sera were considered positive when the optical density (OD) values were ≥0.3 (horizon-
tal lane). All sera were tested with the 48 antigens. Only the Ro antigens showing the highest reactivity are depicted in the figures; ◆ , recombinant 
Ro52; ■ , Ro52 peptide 1–13; •, Ro52 peptide 107–122; , Ro52 peptide 277–292; ❍ , Ro52 peptide 365–382; ▲ , La.Arthritis Research & Therapy    Vol 8 No 1    Fritsch et al.
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study, synthetic peptides 13–24 residues long were used in
an ELISA to analyze the Ro52 and Ro60 antibody response in
mothers whose children have NLE. The whole proteins Ro52,
Ro60 and La were also included in this study. The 192 sera
from a total of 66 mothers in the two different clinical groups I
and II (with or without infants with NLE) as well as the 43 dis-
ease controls were studied. The appearance of protein and
peptide-reactive antibodies was examined before and during
the time of pregnancy, as well as after delivery.
A thorough mapping of autoantibody specificities was under-
taken. The high frequency of IgG antibodies to the whole pro-
teins Ro52, Ro60 and La in all selected sera was notable, but
a large number of discrepancies between the results obtained
via immunodiffusion, Western blotting and ELISA was
observed. This lack of correlation has been described previ-
ously and may be due, for example, to the absence of Ro52 in
total test antigen used in immunodiffusion or to the fact that
the Ro antigen used was extracted from bovine spleen, which
is known to be less effectively recognized by patients' autoan-
tibodies than human Ro [25,26].
A second set of data was obtained by examining the reactivity
of sera with 45 peptides of Ro52 and Ro60 proteins. Eleven
Ro peptides were recognized by IgG antibodies from at least
25% of mothers included in this study. These peptides encom-
pass residues 1–13, 50–64, 93–116, 107–122, 107–126,
236–250, 277–292, 365–382 of Ro52 and residues 18–38,
21–41 and 304–324 of Ro60. Although the actual fragments
176–196 and 200–239 of Ro52 described by Wahren-Herle-
nius and colleagues [23,24] were not tested in this study, thus
precluding any direct conclusion, we noted infrequent reactiv-
ity in the four peptides covering these regions (Ro52 peptides
178–193, 191–208, 206–224, 222–235). While the reactiv-
Figure 2
Reactivity in ELISA of sera from lupus mothers of groups I and II with Ro antigens Reactivity in ELISA of sera from lupus mothers of groups I and II with Ro antigens. Sera were classified into three subgroups: (a), (d) before, (b), (e) 
during, and (c), (f) after pregnancy. The results are expressed in terms of frequency (%) of positive reaction ((a)–(c)) and antibody level (mean optical 
density [OD] values + standard deviation) ((d)–(f)). Mothers' sera were tested at a 1:1,000 dilution and the IgG response only was evaluated. The 
number of samples (number of mothers) was as follows; group I (black bars): (a)–(d), 5 (3); (b)–(e), 8 (5); (c)–(f), 6 (5); group II (white bars): (a)–(d), 
18 (4); (b)–(e), 44 (16); (c)–(f), 12 (7). All samples were systematically tested in at least two independent tests. The results shown in the figure cor-
respond to one complete representative experiment. The sera were considered positive when OD ≥0.3 (visualized by a longitudinal lane in panels 
(d)–(f)). All sera were tested with the 48 antigens. Only the Ro antigens showing reactivity are depicted. For clarity, the first residue of each peptide 
sequence is indicated in the figures (107-1 for 107–122; 107-2 for 107–126). (a)–(c) Student's t test, *0.05 > P > 0.01, **P ≤ 0.01; (d) and (e) 
Mann-Whitney U test, *0.05 > P > 0.005, **P ≤ 0.005.Available online http://arthritis-research.com/content/8/1/R4
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ity of sera with the whole proteins Ro52, Ro60 and La was
high in subgroups of SLE and SS mothers and did not help to
distinguish the group of mothers at risk, the overall level of IgG
antibodies reacting with several Ro peptides, however, was
significantly higher in lupus mothers of group I as compared
with group II. These peptides encompass residues 107–122
and 277–292 of Ro52 and residues 21–41 of Ro60. Antibod-
ies reacting with Ro52 peptides 1–13 and 365–382 were
also particularly elevated in lupus mothers of group I. In con-
trast, no statistically significant difference was observed
between groups I and II of mothers with SS, and low levels of
Ro peptide reactive antibodies were measured in asympto-
matic mothers who gave birth to babies with NLE.
The lack of significant association of any antibody subset in
groups I and II of patients with SS is intriguing. It is not known
whether this result suggests that there are different physio-
pathological mechanisms involved in SLE and SS. This
important question will be examined further in a larger group of
mothers. On the other hand, since La reactivity within the
group of mothers with SLE seems to be significantly more
prevalent in group I compared with group II (Table 3), another
envisaged study will be to evaluate the reactivity of mother's
sera with overlapping La peptides.
An important feature demonstrated in this study was that, dur-
ing the critical window of pregnancy between 18 and 30
weeks of gestation, there was a high level of IgG antibodies
reacting with Ro52 peptides 1–13, 277–292 and 365–382 in
lupus mothers of group I. This result is particularly important to
highlight because these antibodies might play an important
role in the pathogenesis of CHB at an early stage during fetal
cardiac development, and also because the Ro52 sequence
365–382 does correspond to the site of homology with the
serotoninergic 5-HT4-R [12-14]. It has been confirmed
recently that IgG antibodies reacting with peptide 165–185 of
5-HT4-R effectively occurred in a higher proportion of mothers
whose children had CHB [27]. Although a meta-analysis
should be performed to confirm the data, this study raises the
point that tracing IgG antibodies reacting with peptide 365–
382 of Ro52 might be important in patients with lupus to fol-
low at-risk pregnancies.
Figure 3
Reactivity in ELISA of sera collected from lupus mothers of groups I and II during pregnancy Reactivity in ELISA of sera collected from lupus mothers of groups I and II during pregnancy. Sera were classified in four subgroups, corresponding 
to weeks 1–8, 16–20, 26–30 and 31–35 of gestation. The number of sera in each subgroup is indicated (n). Sera were tested at a 1:1,000 dilution. 
The IgG response only was evaluated. The sera were considered positive when OD ≥0.3 (horizontal lane). All sera were tested with the 48 antigens. 
Only the Ro antigens showing reactivity are depicted in the figures. Antigens tested: columns 1, 6 and 9 (black bars), recombinant Ro52, Ro60 and 
La proteins, respectively; columns 2–5 (grey bars), Ro52 peptides 1–13, 107–122, 277–292 and 365–382; columns 7 and 8, Ro60 peptides 21–
41 and 304–324.Arthritis Research & Therapy    Vol 8 No 1    Fritsch et al.
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Our previous studies have provided some important features
concerning the pathological consequences for the fetal heart
of antibodies to 5-HT4-R [12-14]. It would be of interest to
prolong this study by demonstrating the possible physiopatho-
logical role of Ro antibodies reacting with Ro52 peptide 365–
382, and to determine whether the other antibody subsets of
Ro52 antibodies (antibodies reacting with Ro52 peptides 1–
13, 107–122 and 277–292, for example) also generate elec-
trophysiological disturbances compatible with CHB.
Conclusion
Longitudinal analysis of mothers with SLE and SS showed that
in the group of lupus mothers whose at least one child had
NLE, a significantly higher frequency of IgG antibodies to
Ro52 peptides 107–122 and 277–292 was observed.
Between 18 and 30 weeks of gestation, the period of risk,
there was clearly an elevated level of circulating antibodies
reacting with Ro52 peptides 1–13, 277–292 and 365–382.
This result is particularly important since antibodies to Ro52
peptide 365–382 have been shown previously to cross-react
with residues 165–185 of the heart 5-HT4 serotoninergic
receptor and might be pathologically important. The level of
these Ro52 antibody subsets decreased at the end of preg-
nancy and after delivery. IgG antibodies to Ro52 peptides 1–
13, 107–122, 277–292 and 365–382 could therefore be
important to predict a complication in pregnant lupus women
with Ro52 antibodies.
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